Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
about
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Mutant JAK3 phosphoproteomic p ...... acute lymphoblastic leukemia.
@en
type
label
Mutant JAK3 phosphoproteomic p ...... acute lymphoblastic leukemia.
@en
prefLabel
Mutant JAK3 phosphoproteomic p ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P50
P356
P1433
P1476
Mutant JAK3 phosphoproteomic p ...... l acute lymphoblastic leukemia
@en
P2093
H C Murray
I Govaerts
S Bornschein
P2860
P2888
P304
P356
10.1038/LEU.2017.276
P50
P577
2017-08-30T00:00:00Z
P6179
1091401336